DeepMed Research

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients

Completed

Conditions: Stroke

Interventions: Drug: rt-PA

First Posted Date: 2022-06-02

Last Posted Date: 2024-10-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 3058

Registration Number: NCT05401149

Locations: 🇨🇳
Boehringer Ingelheim (China) Investment Co., ltd., Shanghai, China

Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium (Tio)
Drug: Inhaled corticosteroids (ICS)
Drug: Olodaterol (Olo)
Drug: Long-acting β2-agonists (LABA)

First Posted Date: 2022-06-02

Last Posted Date: 2024-08-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 17018

Registration Number: NCT05402020

Locations: 🇨🇳
National Tawain University Hospital, Taipei, China

Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization

Completed

Conditions: Stroke

Interventions: Drug: rt-PA

First Posted Date: 2022-05-27

Last Posted Date: 2024-12-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 113035

Registration Number: NCT05395351

Locations: 🇨🇳
Boehringer Ingelheim (China) Investment Co., ltd., Shanghai, China

1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients

Completed

Conditions: Stroke

Interventions: Drug: rt-PA

First Posted Date: 2022-05-27

Last Posted Date: 2024-10-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12551

Registration Number: NCT05395338

Locations: 🇨🇳
Boehringer Ingelheim (China) Investment Co., ltd., Shanghai, China

Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium+Olodaterol
Drug: Long-acting muscarinic antagonists (LAMAs)
Device: Spiolto Respimat
Drug: Long-acting β2-agonists (LABAs)

First Posted Date: 2022-05-26

Last Posted Date: 2024-12-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 19467

Registration Number: NCT05393245

Locations: 🇨🇳
Health Data Research Center, National Taiwan University, Taiwan, China

A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1810631 - trial formulation 1 (TF1)
Drug: BI 1810631 - new formulation (NF)
Drug: Rabeprazole sodium

First Posted Date: 2022-05-19

Last Posted Date: 2024-10-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 13

Registration Number: NCT05380947

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma

Phase 1

Active, not recruiting

Conditions: Glioblastoma

Interventions: Drug: BI 907828 (Brigimadlin)

First Posted Date: 2022-05-17

Last Posted Date: 2025-02-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT05376800

Locations: 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States
🇺🇸
Mayo Clinic-Arizona, Phoenix, Arizona, United States
🇺🇸
Mayo Clinic Cancer Center, Jacksonville, Florida, United States

and more 4 locations

A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: BI 907828
Drug: Rifampicin
Drug: Itraconazole

First Posted Date: 2022-05-12

Last Posted Date: 2025-05-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 33

Registration Number: NCT05372367

Locations: 🇪🇸
Hospital Quiron. I.C.U., Barcelona, Spain
🇪🇸
Fundación Jiménez Díaz, Madrid, Spain
🇪🇸
CIO Clara Campal, Madrid, Spain

and more 4 locations

Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug

Terminated

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Device: Spiriva® Respimat®
Device: Spiriva® HandiHaler®
Drug: Tiotropium bromide

First Posted Date: 2022-05-05

Last Posted Date: 2025-02-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 9

Registration Number: NCT05362487

Locations: 🇨🇭
Cantonal Hosp. Baselland,Univ.Med.Dept,Liestal, Liestal, Switzerland

A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0001)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1839100
Drug: Placebo
Drug: allyl isothiocyanate (AITC)

First Posted Date: 2022-04-29

Last Posted Date: 2023-07-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 104

Registration Number: NCT05354453

Locations: 🇳🇱
Centre Human Drug Research, Leiden, Netherlands

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy